Highlights and Quick Summary
- Selling, General and Administrative Expense of Revenue for the quarter ending June 30, 2023 was 27.05% (a -55.56% decrease compared to previous quarter)
- Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -19.06%
- Annual Selling, General and Administrative Expense of Revenue for 2022 was 30.36% (a 56.25% increase from previous year)
- Annual Selling, General and Administrative Expense of Revenue for 2021 was 19.43% (a -0.36% decrease from previous year)
- Annual Selling, General and Administrative Expense of Revenue for 2020 was 19.5% (a -21.15% decrease from previous year)
- Twelve month Selling, General and Administrative Expense of Revenue ending June 30, 2023 was 34.12% (a -6.21% decrease compared to previous quarter)
- Twelve month trailing Selling, General and Administrative Expense of Revenue increased by 51.71% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| 34.12% | 36.38% | 30.36% | 22.49% |
Visit stockrow.com/EBS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Selling, General and Administrative Expense of Revenue of Emergent Biosolutions Inc.
Most recent Selling, General and Administrative Expense of Revenueof EBS including historical data for past 10 years.Interactive Chart of Selling, General and Administrative Expense of Revenue of Emergent Biosolutions Inc.
Emergent Biosolutions Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | 27.05% | 60.87% | – | – | – |
| 2022 | 28.49% | 33.42% | 33.42% | 27.58% | 30.36% |
| 2021 | 13.03% | 24.95% | 22.94% | 23.59% | 19.43% |
| 2020 | 14.08% | 19.6% | 19.26% | 36.21% | 19.5% |
| 2019 | 20.06% | 20.85% | 29.11% | 34.31% | 24.73% |
| 2018 | 29.87% | 24.25% | 17.94% | 33.96% | 25.88% |
| 2017 | 21.35% | 23.09% | 31.62% | 30.08% | 25.48% |
| 2016 | 22.93% | 28.47% | 39.37% | 30.8% | 29.28% |
| 2015 | 17.28% | 16.29% | 28.91% | 54.21% | 24.76% |
| 2014 | 17.26% | 21.96% | 27.7% | 55.84% | 26.85% |
| 2013 | 25.89% | 24.64% | 24.87% | 46.47% | 28.1% |
| 2012 | 20.59% | 28.76% | – | – | 26.97% |
Business Profile of Emergent Biosolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic